AVNT vs CE: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: CE is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AVNT and CE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AVNT and CE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Avient Corporation makes formulated materials rather than base chemicals. It buys polymer resin and pigment and sells engineered recipes: masterbatch colorants, functional additives, specialty inks, thermoplastic elastomers, composites and the Dyneema ultra-high-molecular-weight polyethylene fiber line acquired from DSM in 2022. Two reporting segments carry the business. Color, Additives and Inks is the larger one at roughly $2.0 billion of 2025 sales, and Specialty Engineered Materials contributed about $1.2 billion. End markets are spread across packaging, consumer goods, healthcare and pharmaceutical devices, building and construction, transportation, wire and cable, and defense. The company employs around 9,000 people and traces its roots to a 1885 founding, having renamed itself from PolyOne in 2020 after selling the commodity distribution and PVC compounding businesses that used to dominate its sales mix.

Full AVNT guide

Celanese Corporation makes chemicals in two very different businesses. Its Acetyl Chain segment produces acetic acid, vinyl acetate monomer, acetate tow and related derivatives, largely commodity molecules sold on price and cost position, and it generated about ~$2.4B of net sales in the first half of 2026. Engineered Materials, the larger half at roughly ~$2.8B of first-half sales, sells specialty polymers, nylon, elastomers and compounds into automotive, medical, electronics and industrial applications where formulations are specified into a customer's part. Around ~11,400 employees run the plant network, which spans North America, Europe and Asia, with a large equity-affiliate presence in China.

Full CE guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AVNT drivers: Dyneema capacity for defense; Margin expansion from productivity and pricing.
• CE drivers: Deleveraging through cash and asset sales; Acetyl Chain pricing and regional supply dislocation.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Organic volume has been flat to slightly negative for several quarters, so the earnings growth on offer depends on margin gains continuing rather than on demand recovering. For CE, leverage dominates the risk list.

Pick AVNT if you believe its drivers more; CE if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AVNT and CE guides.

AVNT. Q1 2026 adjusted EPS of about $0.83 beat the roughly $0.81 consensus on sales of about $847 million, and full-year guidance was left unchanged. Q2 2026 results are due 6 August 2026, with consensus near $0.89 in adjusted EPS on roughly $899 million of sales. The gap between the trailing P/E near 22 and the forward figure near 12 reflects GAAP earnings that carry restructuring and amortization charges the adjusted figures exclude, so which number an investor uses changes the valuation picture considerably.

CE. Two very different valuations sit on the same company. Equity holders pay roughly half of trailing sales, which looks cheap until the ~$10.6B of net debt is added and the whole enterprise prices at about ~1.7x sales, a fairly ordinary multiple for a chemical producer in a soft cycle. Free cash flow of roughly ~$708M over the trailing twelve months is what services the debt, and first-half operating cash of ~$285M came in below the prior year on a large working-capital build in receivables.

Headline figures (approximate, August 2026): AVNT shows revenue (ttm) ~$3.28 billion, market cap ~$3.5 billion, adjusted eps guidance (2026) ~$2.93 to $3.17, adjusted ebitda guidance (2026) ~$555 to $585 million; CE shows revenue (ttm) ~$9.7B, net income (ttm) ~-$1.2B, driven by goodwill and asset impairments, market cap ~$4.8B at roughly ~$44 per share, net debt ~$10.6B (total debt ~$12.0B less cash ~$1.4B).

AVNT and CE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AVNT and CE exposure against your real portfolio. It is not an investment adviser.